Valiant Laboratories Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Valiant Laboratories rose 151.43% to Rs 1.76 crore in the quarter ended March 2026 as against Rs 0.70 crore during the previous quarter ended March 2025. Sales rose 59.16% to Rs 91.98 crore in the quarter ended March 2026 as against Rs 57.79 crore during the previous quarter ended March 2025.

For the full year,net loss reported to Rs 3.27 crore in the year ended March 2026 as against net loss of Rs 2.20 crore during the previous year ended March 2025. Sales rose 78.04% to Rs 237.47 crore in the year ended March 2026 as against Rs 133.38 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Net loss of Valiant Laboratories reported to Rs 7.06 crore in the quarter ended December 2025 as against net profit of Rs 2.35 crore during the previous quarter ended December 2024. Sales rose 48.91% to Rs 52.46 crore in the quarter ended December 2025 as against Rs 35.23 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Valiant Laboratories will hold a meeting of the Board of Directors of the Company on 11 February 2026.

Powered by Capital Market - Live News